Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow VALN
Valneva SE Sponsored ADR (VALN) P/E ratio
As of 16 October 2026, Valneva SE Sponsored ADR (VALN) trades at a P/E ratio of 59.7×. Over the past ten years it has ranged from 0.0× (March 2024) to 75.9× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 23.0× | 22.91% |
| FY2024 | 18.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 66.5× | 280.11% |
| Mar 2025 | 17.5× | (46.79%) |
| Mar 2024 | 32.9× | — |
| Sep 2023 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| STTK Shattuck Labs, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| CRMD CorMedix Inc compare | 3.0× |
| PBYI Puma Biotechnology, Inc. compare | 18.2× |
| VALN Valneva SE Sponsored ADR | 59.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)